世界の重症筋無力症市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Myasthenia Gravis Disease Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3983 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、重症筋無力症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物治療、手術、造血幹細胞移植（HSCT）、その他）、用途別市場規模（病院、診療所、学術研究機関）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・重症筋無力症の市場動向 ・企業の競争状況、市場シェア ・重症筋無力症の種類別市場規模（薬物治療、手術、造血幹細胞移植（HSCT）、その他） ・重症筋無力症の用途別市場規模（病院、診療所、学術研究機関） ・重症筋無力症の北米市場規模2016-2027（アメリカ、カナダ） ・重症筋無力症のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・重症筋無力症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・重症筋無力症の中南米市場規模2016-2027（メキシコ、ブラジル） ・重症筋無力症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bausch Health、Sun Pharmaceuticals Industries、Novartis Pharmaceuticals、Teva Pharmaceutical Industries、Cipla、Roche、Apotex Corporation、Pfizer、Bristol-Myers And Company） ・結論

Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be sudden. Those affected often have a large thymus gland or develop a thymoma.
Myasthenia gravis is generally treated with medications known as acetylcholinesterase inhibitors such as neostigmineand pyridostigmine. Immunosuppressants, such as prednisone or azathioprine, may also be used. The surgical removal of the thymus gland may improve symptoms in certain cases. Plasmapheresis and high dose intravenous immunoglobulin may be used during sudden flares of the condition. If the breathing muscles become significantly weak, mechanical ventilation may be required.

Market Analysis and Insights: Global Myasthenia Gravis Disease Market
The global Myasthenia Gravis Disease market size is projected to reach US$ 1612.8 million by 2026, from US$ 897.2 million in 2019, at a CAGR of 8.6% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myasthenia Gravis Disease market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myasthenia Gravis Disease market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myasthenia Gravis Disease market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myasthenia Gravis Disease market.

Global Myasthenia Gravis Disease Scope and Market Size
Myasthenia Gravis Disease market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Medication
Surgery
Hematopoietic Stem Cell Transplantation (HSCT)
Other

Segment by Application
Hospitals
Clinics
Academic Research Institutes

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Bausch Health
Sun Pharmaceuticals Industries
Novartis Pharmaceuticals
Teva Pharmaceutical Industries
Cipla
Roche
Apotex Corporation
Pfizer
Bristol-Myers And Company

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myasthenia Gravis Disease Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Medication
1.2.3 Surgery
1.2.4 Hematopoietic Stem Cell Transplantation (HSCT)
1.2.5 Other
1.3 Market by Application
1.3.1 Global Myasthenia Gravis Disease Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Academic Research Institutes
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Myasthenia Gravis Disease Market Perspective (2016-2027)
2.2 Myasthenia Gravis Disease Growth Trends by Regions
2.2.1 Myasthenia Gravis Disease Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myasthenia Gravis Disease Historic Market Share by Regions (2016-2021)
2.2.3 Myasthenia Gravis Disease Forecasted Market Size by Regions (2022-2027)
2.3 Myasthenia Gravis Disease Industry Dynamic
2.3.1 Myasthenia Gravis Disease Market Trends
2.3.2 Myasthenia Gravis Disease Market Drivers
2.3.3 Myasthenia Gravis Disease Market Challenges
2.3.4 Myasthenia Gravis Disease Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Disease Players by Revenue
3.1.1 Global Top Myasthenia Gravis Disease Players by Revenue (2016-2021)
3.1.2 Global Myasthenia Gravis Disease Revenue Market Share by Players (2016-2021)
3.2 Global Myasthenia Gravis Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myasthenia Gravis Disease Revenue
3.4 Global Myasthenia Gravis Disease Market Concentration Ratio
3.4.1 Global Myasthenia Gravis Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Disease Revenue in 2020
3.5 Myasthenia Gravis Disease Key Players Head office and Area Served
3.6 Key Players Myasthenia Gravis Disease Product Solution and Service
3.7 Date of Enter into Myasthenia Gravis Disease Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Myasthenia Gravis Disease Breakdown Data by Type
4.1 Global Myasthenia Gravis Disease Historic Market Size by Type (2016-2021)
4.2 Global Myasthenia Gravis Disease Forecasted Market Size by Type (2022-2027)

5 Myasthenia Gravis Disease Breakdown Data by Application
5.1 Global Myasthenia Gravis Disease Historic Market Size by Application (2016-2021)
5.2 Global Myasthenia Gravis Disease Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Myasthenia Gravis Disease Market Size (2016-2027)
6.2 North America Myasthenia Gravis Disease Market Size by Type
6.2.1 North America Myasthenia Gravis Disease Market Size by Type (2016-2021)
6.2.2 North America Myasthenia Gravis Disease Market Size by Type (2022-2027)
6.2.3 North America Myasthenia Gravis Disease Market Size by Type (2016-2027)
6.3 North America Myasthenia Gravis Disease Market Size by Application
6.3.1 North America Myasthenia Gravis Disease Market Size by Application (2016-2021)
6.3.2 North America Myasthenia Gravis Disease Market Size by Application (2022-2027)
6.3.3 North America Myasthenia Gravis Disease Market Size by Application (2016-2027)
6.4 North America Myasthenia Gravis Disease Market Size by Country
6.4.1 North America Myasthenia Gravis Disease Market Size by Country (2016-2021)
6.4.2 North America Myasthenia Gravis Disease Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Myasthenia Gravis Disease Market Size (2016-2027)
7.2 Europe Myasthenia Gravis Disease Market Size by Type
7.2.1 Europe Myasthenia Gravis Disease Market Size by Type (2016-2021)
7.2.2 Europe Myasthenia Gravis Disease Market Size by Type (2022-2027)
7.2.3 Europe Myasthenia Gravis Disease Market Size by Type (2016-2027)
7.3 Europe Myasthenia Gravis Disease Market Size by Application
7.3.1 Europe Myasthenia Gravis Disease Market Size by Application (2016-2021)
7.3.2 Europe Myasthenia Gravis Disease Market Size by Application (2022-2027)
7.3.3 Europe Myasthenia Gravis Disease Market Size by Application (2016-2027)
7.4 Europe Myasthenia Gravis Disease Market Size by Country
7.4.1 Europe Myasthenia Gravis Disease Market Size by Country (2016-2021)
7.4.2 Europe Myasthenia Gravis Disease Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Myasthenia Gravis Disease Market Size (2016-2027)
8.2 Asia-Pacific Myasthenia Gravis Disease Market Size by Type
8.2.1 Asia-Pacific Myasthenia Gravis Disease Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myasthenia Gravis Disease Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myasthenia Gravis Disease Market Size by Type (2016-2027)
8.3 Asia-Pacific Myasthenia Gravis Disease Market Size by Application
8.3.1 Asia-Pacific Myasthenia Gravis Disease Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myasthenia Gravis Disease Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myasthenia Gravis Disease Market Size by Application (2016-2027)
8.4 Asia-Pacific Myasthenia Gravis Disease Market Size by Region
8.4.1 Asia-Pacific Myasthenia Gravis Disease Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myasthenia Gravis Disease Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Myasthenia Gravis Disease Market Size (2016-2027)
9.2 Latin America Myasthenia Gravis Disease Market Size by Type
9.2.1 Latin America Myasthenia Gravis Disease Market Size by Type (2016-2021)
9.2.2 Latin America Myasthenia Gravis Disease Market Size by Type (2022-2027)
9.2.3 Latin America Myasthenia Gravis Disease Market Size by Type (2016-2027)
9.3 Latin America Myasthenia Gravis Disease Market Size by Application
9.3.1 Latin America Myasthenia Gravis Disease Market Size by Application (2016-2021)
9.3.2 Latin America Myasthenia Gravis Disease Market Size by Application (2022-2027)
9.3.3 Latin America Myasthenia Gravis Disease Market Size by Application (2016-2027)
9.4 Latin America Myasthenia Gravis Disease Market Size by Country
9.4.1 Latin America Myasthenia Gravis Disease Market Size by Country (2016-2021)
9.4.2 Latin America Myasthenia Gravis Disease Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Myasthenia Gravis Disease Market Size (2016-2027)
10.2 Middle East & Africa Myasthenia Gravis Disease Market Size by Type
10.2.1 Middle East & Africa Myasthenia Gravis Disease Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myasthenia Gravis Disease Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myasthenia Gravis Disease Market Size by Type (2016-2027)
10.3 Middle East & Africa Myasthenia Gravis Disease Market Size by Application
10.3.1 Middle East & Africa Myasthenia Gravis Disease Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myasthenia Gravis Disease Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myasthenia Gravis Disease Market Size by Application (2016-2027)
10.4 Middle East & Africa Myasthenia Gravis Disease Market Size by Country
10.4.1 Middle East & Africa Myasthenia Gravis Disease Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myasthenia Gravis Disease Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Bausch Health
11.1.1 Bausch Health Company Details
11.1.2 Bausch Health Business Overview
11.1.3 Bausch Health Myasthenia Gravis Disease Introduction
11.1.4 Bausch Health Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.1.5 Bausch Health Recent Development
11.2 Sun Pharmaceuticals Industries
11.2.1 Sun Pharmaceuticals Industries Company Details
11.2.2 Sun Pharmaceuticals Industries Business Overview
11.2.3 Sun Pharmaceuticals Industries Myasthenia Gravis Disease Introduction
11.2.4 Sun Pharmaceuticals Industries Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.2.5 Sun Pharmaceuticals Industries Recent Development
11.3 Novartis Pharmaceuticals
11.3.1 Novartis Pharmaceuticals Company Details
11.3.2 Novartis Pharmaceuticals Business Overview
11.3.3 Novartis Pharmaceuticals Myasthenia Gravis Disease Introduction
11.3.4 Novartis Pharmaceuticals Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.3.5 Novartis Pharmaceuticals Recent Development
11.4 Teva Pharmaceutical Industries
11.4.1 Teva Pharmaceutical Industries Company Details
11.4.2 Teva Pharmaceutical Industries Business Overview
11.4.3 Teva Pharmaceutical Industries Myasthenia Gravis Disease Introduction
11.4.4 Teva Pharmaceutical Industries Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.4.5 Teva Pharmaceutical Industries Recent Development
11.5 Cipla
11.5.1 Cipla Company Details
11.5.2 Cipla Business Overview
11.5.3 Cipla Myasthenia Gravis Disease Introduction
11.5.4 Cipla Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.5.5 Cipla Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Myasthenia Gravis Disease Introduction
11.6.4 Roche Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.6.5 Roche Recent Development
11.7 Apotex Corporation
11.7.1 Apotex Corporation Company Details
11.7.2 Apotex Corporation Business Overview
11.7.3 Apotex Corporation Myasthenia Gravis Disease Introduction
11.7.4 Apotex Corporation Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.7.5 Apotex Corporation Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Myasthenia Gravis Disease Introduction
11.8.4 Pfizer Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.8.5 Pfizer Recent Development
11.9 Bristol-Myers And Company
11.9.1 Bristol-Myers And Company Company Details
11.9.2 Bristol-Myers And Company Business Overview
11.9.3 Bristol-Myers And Company Myasthenia Gravis Disease Introduction
11.9.4 Bristol-Myers And Company Revenue in Myasthenia Gravis Disease Business (2016-2021)
11.9.5 Bristol-Myers And Company Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Myasthenia Gravis Disease Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Medication
Table 3. Key Players of Surgery
Table 4. Key Players of Hematopoietic Stem Cell Transplantation (HSCT)
Table 5. Key Players of Other
Table 6. Global Myasthenia Gravis Disease Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Myasthenia Gravis Disease Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Myasthenia Gravis Disease Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Myasthenia Gravis Disease Market Share by Regions (2016-2021)
Table 10. Global Myasthenia Gravis Disease Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Myasthenia Gravis Disease Market Share by Regions (2022-2027)
Table 12. Myasthenia Gravis Disease Market Trends
Table 13. Myasthenia Gravis Disease Market Drivers
Table 14. Myasthenia Gravis Disease Market Challenges
Table 15. Myasthenia Gravis Disease Market Restraints
Table 16. Global Myasthenia Gravis Disease Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Myasthenia Gravis Disease Market Share by Players (2016-2021)
Table 18. Global Top Myasthenia Gravis Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease as of 2020)
Table 19. Ranking of Global Top Myasthenia Gravis Disease Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Myasthenia Gravis Disease Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Myasthenia Gravis Disease Product Solution and Service
Table 23. Date of Enter into Myasthenia Gravis Disease Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Myasthenia Gravis Disease Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Myasthenia Gravis Disease Revenue Market Share by Type (2016-2021)
Table 27. Global Myasthenia Gravis Disease Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Myasthenia Gravis Disease Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Myasthenia Gravis Disease Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Myasthenia Gravis Disease Revenue Market Share by Application (2016-2021)
Table 31. Global Myasthenia Gravis Disease Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Myasthenia Gravis Disease Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Myasthenia Gravis Disease Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Myasthenia Gravis Disease Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Myasthenia Gravis Disease Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Myasthenia Gravis Disease Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Myasthenia Gravis Disease Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Myasthenia Gravis Disease Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Myasthenia Gravis Disease Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Myasthenia Gravis Disease Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Myasthenia Gravis Disease Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Myasthenia Gravis Disease Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Myasthenia Gravis Disease Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Myasthenia Gravis Disease Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Myasthenia Gravis Disease Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Myasthenia Gravis Disease Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Myasthenia Gravis Disease Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Myasthenia Gravis Disease Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Myasthenia Gravis Disease Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Myasthenia Gravis Disease Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Myasthenia Gravis Disease Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Myasthenia Gravis Disease Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Myasthenia Gravis Disease Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Myasthenia Gravis Disease Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Myasthenia Gravis Disease Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Myasthenia Gravis Disease Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Myasthenia Gravis Disease Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Myasthenia Gravis Disease Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Myasthenia Gravis Disease Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Myasthenia Gravis Disease Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Myasthenia Gravis Disease Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Myasthenia Gravis Disease Market Size by Country (2022-2027) & (US$ Million)
Table 63. Bausch Health Company Details
Table 64. Bausch Health Business Overview
Table 65. Bausch Health Myasthenia Gravis Disease Product
Table 66. Bausch Health Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 67. Bausch Health Recent Development
Table 68. Sun Pharmaceuticals Industries Company Details
Table 69. Sun Pharmaceuticals Industries Business Overview
Table 70. Sun Pharmaceuticals Industries Myasthenia Gravis Disease Product
Table 71. Sun Pharmaceuticals Industries Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 72. Sun Pharmaceuticals Industries Recent Development
Table 73. Novartis Pharmaceuticals Company Details
Table 74. Novartis Pharmaceuticals Business Overview
Table 75. Novartis Pharmaceuticals Myasthenia Gravis Disease Product
Table 76. Novartis Pharmaceuticals Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 77. Novartis Pharmaceuticals Recent Development
Table 78. Teva Pharmaceutical Industries Company Details
Table 79. Teva Pharmaceutical Industries Business Overview
Table 80. Teva Pharmaceutical Industries Myasthenia Gravis Disease Product
Table 81. Teva Pharmaceutical Industries Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 82. Teva Pharmaceutical Industries Recent Development
Table 83. Cipla Company Details
Table 84. Cipla Business Overview
Table 85. Cipla Myasthenia Gravis Disease Product
Table 86. Cipla Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 87. Cipla Recent Development
Table 88. Roche Company Details
Table 89. Roche Business Overview
Table 90. Roche Myasthenia Gravis Disease Product
Table 91. Roche Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 92. Roche Recent Development
Table 93. Apotex Corporation Company Details
Table 94. Apotex Corporation Business Overview
Table 95. Apotex Corporation Myasthenia Gravis Disease Product
Table 96. Apotex Corporation Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 97. Apotex Corporation Recent Development
Table 98. Pfizer Company Details
Table 99. Pfizer Business Overview
Table 100. Pfizer Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 101. Pfizer Recent Development
Table 102. Bristol-Myers And Company Company Details
Table 103. Bristol-Myers And Company Business Overview
Table 104. Bristol-Myers And Company Myasthenia Gravis Disease Product
Table 105. Bristol-Myers And Company Revenue in Myasthenia Gravis Disease Business (2016-2021) & (US$ Million)
Table 106. Bristol-Myers And Company Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myasthenia Gravis Disease Market Share by Type: 2020 VS 2027
Figure 2. Medication Features
Figure 3. Surgery Features
Figure 4. Hematopoietic Stem Cell Transplantation (HSCT) Features
Figure 5. Other Features
Figure 6. Global Myasthenia Gravis Disease Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Academic Research Institutes Case Studies
Figure 10. Myasthenia Gravis Disease Report Years Considered
Figure 11. Global Myasthenia Gravis Disease Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Myasthenia Gravis Disease Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Myasthenia Gravis Disease Market Share by Regions: 2020 VS 2027
Figure 14. Global Myasthenia Gravis Disease Market Share by Regions (2022-2027)
Figure 15. Global Myasthenia Gravis Disease Market Share by Players in 2020
Figure 16. Global Top Myasthenia Gravis Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Myasthenia Gravis Disease Revenue in 2020
Figure 18. Global Myasthenia Gravis Disease Revenue Market Share by Type (2016-2021)
Figure 19. Global Myasthenia Gravis Disease Revenue Market Share by Type (2022-2027)
Figure 20. North America Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Myasthenia Gravis Disease Market Share by Type (2016-2027)
Figure 22. North America Myasthenia Gravis Disease Market Share by Application (2016-2027)
Figure 23. North America Myasthenia Gravis Disease Market Share by Country (2016-2027)
Figure 24. United States Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Myasthenia Gravis Disease Market Share by Type (2016-2027)
Figure 28. Europe Myasthenia Gravis Disease Market Share by Application (2016-2027)
Figure 29. Europe Myasthenia Gravis Disease Market Share by Country (2016-2027)
Figure 30. Germany Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Myasthenia Gravis Disease Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Myasthenia Gravis Disease Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Myasthenia Gravis Disease Market Share by Region (2016-2027)
Figure 40. China Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Myasthenia Gravis Disease Market Share by Type (2016-2027)
Figure 48. Latin America Myasthenia Gravis Disease Market Share by Application (2016-2027)
Figure 49. Latin America Myasthenia Gravis Disease Market Share by Country (2016-2027)
Figure 50. Mexico Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Myasthenia Gravis Disease Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Myasthenia Gravis Disease Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Myasthenia Gravis Disease Market Share by Country (2016-2027)
Figure 56. Turkey Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Myasthenia Gravis Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Bausch Health Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 60. Sun Pharmaceuticals Industries Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 61. Novartis Pharmaceuticals Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 62. Teva Pharmaceutical Industries Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 63. Cipla Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 64. Roche Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 65. Apotex Corporation Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 66. Pfizer Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 67. Bristol-Myers And Company Revenue Growth Rate in Myasthenia Gravis Disease Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---